Tim is either dumb, or attempting to start a rumor on the THLD message board. It's interesting , because he consistently writes about how nobody who matters, pays attention to these boards.
He is continually writing his " concerns " about enrollment efforts pertaining to the newly initiated MAESTRO trial. He " Heard " that THLD is having problems recruiting, and may need to go outside of the good ole US of A. How his " Source " was able to figure that out in such a short period of time is beyond me. But wait, maybe Tim is correct with his information. Let's check THLD's Website !
"SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 01/25/13 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Threshold's partner Merck KGaA, Darmstadt, Germany, through its division Merck Serono, initiated the global Phase 3 MAESTRO study assessing the efficacy and safety of investigational hypoxia-targeted drug TH-302 in combination with gemcitabine in patients with previously untreated, locally advanced unresectable or metastatic pancreatic adenocarcinoma.". THLD-
Hhhhhhmmmmmm. Tim is correct !!! THLD is going outside of the US !! Because it says ". GLOBAL ". Global ????? Hhhhhmmmmm. Yup !!! That means outside of the US !! TIM IS CORRECT FOLKS !!!
If you don't understand the importance of a global enrollment decision quit buying stocks and go into mutual funds because you don't have the grey matter to be a successful investor.
Since Merck KGaA has exclusive global commercialization rights and they are paying most of the trial cost and are leadingthe trial it only makes sense that the trial would be done on a global basis.
By doing so, they can complete enrollment faster leading to faster completion of the phase three trial, and initiate marketing of TH-302 globally by making doctors in countries outside the US aware of the drug. The US is not the country with people dying from pancreatic cancer and this will extend TH-302s benefit to people everywhere.